rtterney Docket # 5482-2

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Yuen-Liang LAI et al.

Serial No.:

10/803,666

Filed: March 18, 2004

For:

Use of Arsenic-Containing Pharmaceutical Composition in Combination with Radiation

Therapy for Cancer Treatment

Examiner: Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 20, 2005

(Date of Deposit)

Kent H. Cheng

Signature

September 20, 2005 Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.

It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted, COHEN, PONTANI, LIEBERMAN & PAVANE

By:

Kent H. Cheng Reg. No. 33,849

551 Fifth Avenue, Suite 1210 New York, New York 10176

(212) 687-2770

Dated: September 20, 2005

Under Paperwork Reduction Act of 1995, no persons are required to	U.S. Patent and Trademarl	PTO/SB/08A (04-03) ved for use through 04/30/2003. OMB 0651-0031 c Office; U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number	
Substitute for Form 1449/PTO	Complete if Known		
	Application Number	10/803,666	
INFORMATION DISCLOSURE	Filing Date	March 18, 2004	
STATEMENT BY APPLICANT (Use as many sheets as necessary)	First Named Inventor	Yuen-Liang LAI	
	Art Unit		
	Examiner Name		
Sheet 1 of 2	Attorney Docket Number	5482-2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind-Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		, %	
		US-			
		US-		· ·	
	***************************************	US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			
		US-			
	<u>.</u> .	US-			,
		US-			
-		US-			
P+-		US-			

		F	OREIGN PA	TENT DOCUMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	T _e
initials.	NO.	Country Code ³⁻ Number ⁴⁻ Kind-Code ⁵ (if known	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	

			<u>.</u>	· · · · · · · · · · · · · · · · · · ·		······································
				-		

Examiner Signature	Date Considered	**************************************	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO				C	omplete if Known
				Application Number	10/803,666
INFORMATION DISCLOSURE			SCI OSLID	Filing Date	March 18, 2004
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Yuen-Liang LAI
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	5482-2

Examiner Initials*	Cite	NON PATENT LITERATURE DOCUMENTS	T == 7
Examiner initials*	No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
		X. Li et al., Arsenic Trioxide Inhibits Proliferation and Induces Apoptosis in Pancreatic Cancer Cells, Anticancer Research Vol. 22, pp. 2205-2214 (2002)	
	1	Talleteatte Cancer Cens, Anticancer Research Vol. 22, pp. 2203-2214 (2002)	_
			┢
-			
<u>-</u>			
			\vdash

Examiner Date Signature Considered	
Signature Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.